Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
What Are the Key Milestones in the Esketamine Market’s Growth Trajectory From 2025 To 2034?
The growth of the esketamine market has been swift in the past few years. It is projected to expand from a worth of $1.37 billion in 2024 to a value of $1.52 billion in 2025, at a compound annual growth rate (CAGR) of 11.2%. This growth during the historic period could be credited to a rise in the patient count, a global increase in the incidence of mental health disorders, improved awareness about the disease condition, a growing demand for new treatment possibilities, and advantageous regulatory authorizations.
It is projected that the esketamine market will experience a swift expansion in the upcoming years, reaching an estimated value of $2.31 billion in 2029, growing at an 11.0% compound annual growth rate (CAGR). This growth can be credited to factors such as a higher occurrence of treatment-resistant depression, a boost in investment for research and development initiatives, the desire for intelligent healthcare infrastructure, the rising popularity of telehealth solutions, and the escalating recognition of esketamine as a potent cure. Key trends per the forecast include collaborations between biopharmaceutical firms and mental health agencies, the utilization of robots in healthcare, personalized treatment approaches, the emergence of sensor-based gadgets, and the feasibility of combination treatments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp
Which Primay Drivers Are Accelerating Growth in the Esketamine Market?
The rise in cases of treatment-resistant depression (TRD) is anticipated to fuel the expansion of the esketamine market in the future years. TRD is characterized by unresponsive depression after undertaking at least two different antidepressant medications with the right dosages for the appropriate length of time. The surge in TRD cases can be attributed to the insufficient effectiveness of standard antidepressants, resulting in sustained and recurrent depressive episodes. Esketamine assists in managing TRD through a quick-response mechanism that focuses on NMDA receptors, providing solace to patients who are unresponsive to traditional antidepressants. For example, the National Institute of Mental Health (NIMH), a US federal agency, revealed that approximately 30% of US individuals dealing with major depressive disorder were unresponsive to standard treatments in 2023. Consequently, the escalating incidence of treatment-resistant depression is propelling the growth of the esketamine market.
Which Primary Segments of the Esketamine Market Are Driving Growth and Industry Transformations?
The esketamine market covered in this report is segmented –
1) By Type: Oral Medications, Injection, Nasal Spray, Other Types
2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders
3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients
4) By Application: General Anesthetic, Treatment-Resistant Depression
5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
Subsegments:
1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets
2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection
3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray
4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp
Which Regions Are Key Players in the Growth of the Esketamine Market?
North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive the Esketamine Market’s Growth?
Leading players in the esketamine market are steering their efforts towards creating better treatment options like monotherapy, to exceed what a placebo can provide in terms of symptom relief for depression. Monotherapy only involves a single type of treatment or drug for tackling a disease or medical condition instead of implementing multiple therapies in synchrony. For example, in January 2025, U.S based pharmaceutical giant, Johnson & Johnson, declared that SPRAVATO (esketamine) had been given the official nod by U.S. Food and Drug Administration (FDA) as the exclusive monotherapy for adults who are resistant to the standard treatments available for depression also known as TRD. The approval, backed by clinical trials, proved that SPRAVATO could quickly alleviate symptoms of depression, with substantial improvements noticed in under a day’s time. This monumental innovation caters to nearly 30% of people who remain unresponsive to traditional antidepressants thus completely replacing the need for additional oral medication. Despite its promising safety credentials, SPRAVATO is dispensed under a Risk Evaluation and Mitigation Strategy (REMS) to handle any potential side-effects. This landmark achievement underscores an enormous leap in the field of TRD treatment, infusing fresh optimism for enhanced patient recovery.
View the full report here:
https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report
What Parameters Are Used to Define the Esketamine Market?
Esketamine refers to a fast-acting anesthetic and antidepressant derived from ketamine, known for its NMDA receptor antagonist properties. It is used for treatment-resistant depression and major depressive disorder with suicidal ideation, administered as a nasal spray under medical supervision.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23393
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model